
  
    
      
        Background_NNP
        The_DT early_JJ diagnosis_NN of_IN ovarian_NN cancer_NN has_VBZ the_DT potential_NN
        to_TO dramatically_RB reduce_VB the_DT mortality_NN associated_VBN with_IN this_DT
        disease_NN ._. Recently_RB ,_, the_DT use_NN of_IN surface-enhanced_JJ laser_NN
        desorption_NN /_NN ionization_NN (_( SELDI_NNP )_) time-of-flight_JJ mass_NN
        spectrometry_NN profiling_VBG of_IN patient_NN serum_NN proteins_NNS ,_, combined_VBN
        with_IN advanced_VBD data_NNS mining_NN algorithms_NNS ,_, to_TO detect_VB protein_NN
        patterns_NNS associated_VBN with_IN malignancy_NN ,_, has_VBZ been_VBN reported_VBN as_IN a_DT
        promising_JJ field_NN of_IN research_NN to_TO achieve_VB the_DT goal_NN of_IN early_JJ
        cancer_NN detection_NN [_NN 1_CD 2_CD 3_CD 4_CD 5_CD ]_NN ._. Several_JJ reports_NNS have_VBP
        detailed_JJ the_DT ability_NN of_IN this_DT proteomic_JJ method_NN to_TO diagnose_NN
        the_DT difference_NN between_IN ovarian_NN cancer_NN [_NN 6_CD 7_CD 8_CD ]_NN ,_, prostate_NN
        cancer_NN [_NN 9_CD 10_CD 11_CD 12_CD 13_CD ]_NN ,_, and_CC bladder_NN cancer_NN [_NN 13_CD 14_CD ]_NN ._.
        Much_JJ of_IN the_DT effort_NN in_IN these_DT analyses_NNS has_VBZ focused_VBN on_IN the_DT use_NN
        of_IN a_DT variety_NN of_IN data_NNS mining_NN tools_NNS such_JJ as_IN the_DT evaluation_NN of_IN
        prostate_NN cancer_NN using_VBG peaks_NNS in_IN the_DT mass_NN to_TO charge_VB (_( M_NNP /_NN Z_NNP )_)
        region_NN between_IN 2_CD K_NNP and_CC 40_CD K_NNP combined_VBD with_IN boosted_VBD decision_NN
        tree_NN analysis_NN [_NN 10_CD ]_NN to_TO try_VB to_TO detect_VB patterns_NNS that_WDT allow_VBP
        the_DT diagnosis_NN of_IN cancer_NN versus_CC non-cancer_JJ ._. The_DT use_NN of_IN
        similar_JJ technology_NN to_TO evaluate_VB bladder_NN cancer_NN has_VBZ also_RB been_VBN
        reported_VBN [_NN 13_CD 14_CD ]_NN ._. Thus_RB ,_, this_DT field_NN represents_VBZ an_DT active_JJ
        area_NN of_IN current_JJ research_NN ._. For_IN example_NN ,_, a_DT recent_JJ report_NN by_IN
        the_DT Clinical_NNP Proteomics_NNP Program_NNP Databank_NNP has_VBZ demonstrated_VBN
        that_IN the_DT use_NN of_IN genetic_JJ algorithms_NNS coupled_VBN with_IN clustering_VBG
        analysis_NN has_VBZ resulted_VBN in_IN rule_NN sets_NNS that_WDT can_MD predict_VB ovarian_NN
        cancers_NNS (_( including_VBG samples_NNS from_IN patients_NNS with_IN stage_NN 1_CD
        disease_NN )_) with_IN 100_CD %_NN sensitivity_NN and_CC 96_CD %_NN specificity_NN [_NN 6_CD ]_NN ._.
        These_DT results_NNS have_VBP been_VBN extended_VBN by_IN the_DT same_JJ group_NN to_TO
        include_VB a_DT larger_JJR series_NN of_IN ovarian_NN cancer_NN patients_NNS as_RB well_RB
        as_IN prostate_NN cancer_NN patients_NNS [_NN 7_CD 9_CD ]_NN ._. The_DT Clinical_NNP
        Proteomics_NNP Program_NNP Databank_NNP has_VBZ provided_VBN three_CD sets_NNS of_IN
        ovarian_NN cancer_NN data_NNS to_TO the_DT scientific_JJ community_NN without_IN
        restriction_NN ._. These_DT data_NNS sets_NNS include_VBP Lancet_NNP Ovarian_NNP Data_NNP
        2_CD -_: 16_CD -_: 02_CD used_VBN in_IN the_DT study_NN noted_VBD above_IN [_NN 6_CD ]_NN ._. This_DT study_NN
        consisted_VBD of_IN a_DT total_NN of_IN 100_CD control_NN ,_, 100_CD cancer_NN ,_, and_CC 16_CD
        benign_JJ disease_NN samples_NNS run_VBP on_IN a_DT Ciphergen_NNP H_NNP 4_CD ProteinChip_NNP
        array_NN (_( since_IN discontinued_VBN )_) ._. The_DT samples_NNS were_VBD manually_RB
        processed_VBN ._. The_DT data_NNS was_VBD posted_VBN after_IN baseline_NN subtraction_NN ._.
        The_DT second_JJ data_NN set_VBN ,_, Ovarian_NNP Dataset_NNP 4_CD -_: 3_CD -_: 02_CD consist_VBP of_IN the_DT
        same_JJ samples_NNS as_IN the_DT first_JJ but_CC the_DT samples_NNS were_VBD run_VBN on_IN a_DT
        Ciphergen_NNP WCX_NNP 2_CD ProteinChip_NNP array_NN ._. The_DT samples_NNS were_VBD manually_RB
        prepared_VBN and_CC the_DT data_NNS was_VBD posted_VBN with_IN baseline_NN subtraction_NN ._.
        A_DT model_NN diagnostic_JJ rule_NN based_VBN on_IN this_DT dataset_NN is_VBZ published_VBN
        on_IN the_DT website_NN ,_, but_CC no_DT data_NNS is_VBZ given_VBN regarding_VBG the_DT rules_NNS
        sensitivity_NN or_CC specificity_NN ._. In_IN this_DT report_NN ,_, we_PRP analyze_VBP the_DT
        third_JJ Ovarian_NNP Dataset_NNP 8_CD -_: 7_CD -_: 02_CD and_CC corresponding_JJ sample_NN
        information_NN downloaded_JJ from_IN the_DT Clinical_NNP Proteomics_NNP Program_NNP
        Databank_NNP website_NN [_NN 7_CD ]_NN ._. This_DT set_NN of_IN data_NNS consists_VBZ of_IN serum_NN
        profiles_NNS of_IN 162_CD subjects_NNS with_IN ovarian_NN cancer_NN and_CC 91_CD
        non-cancer_JJ control_NN subjects_NNS ._. The_DT cancer_NN group_NN may_MD be_VB
        further_RBR divided_VBN into_IN 28_CD stage_NN 1_CD patients_NNS ,_, 20_CD stage_NN 2_CD
        patients_NNS ,_, 99_CD stage_NN 3_CD patients_NNS ,_, 12_CD stage_NN 4_CD patients_NNS ,_, and_CC 3_CD
        no_DT stage_NN specified_VBD patients_NNS ._. For_IN each_DT subject_VB a_DT set_NN of_IN data_NNS
        consisting_VBG of_IN intensities_NNS at_IN 15_CD ,_, 154_CD distinct_JJ M_NNP /_NN Z_NNP values_NNS
        ranging_VBG from_IN 0_CD ._. 0000786_CD to_TO 19995_CD ._. 513_CD was_VBD available_JJ for_IN
        analysis_NN ._. This_DT dataset_NN was_VBD constructed_VBN using_VBG the_DT Ciphergen_NNP
        WCX_NNP 2_CD ProteinChip_NNP array_NN ._. All_DT the_DT steps_NNS of_IN preparing_VBG the_DT
        chips_NNS for_IN sample_NN analysis_NN were_VBD preformed_JJ robotically_RB ,_, and_CC
        the_DT raw_JJ data_NN without_IN baseline_NN subtraction_NN was_VBD posted_VBN for_IN
        download_NN ._. A_DT model_NN rule_NN claiming_VBG 100_CD %_NN sensitivity_NN and_CC
        specificity_NN is_VBZ also_RB given_VBN ._. Additional_JJ details_NNS of_IN
        experimental_JJ data_NNS collection_NN may_MD be_VB found_VBN at_IN the_DT Clinical_NNP
        Proteomics_NNP Data_NNP Bank_NNP [_NN 5_CD ]_NN ._. In_IN addition_NN to_TO the_DT various_JJ
        methods_NNS of_IN preparing_VBG and_CC running_VBG the_DT samples_NNS on_IN the_DT mass_NN
        spectrometer_NN ,_, the_DT optimal_NN steps_NNS in_IN processing_VBG the_DT raw_JJ data_NN
        from_IN the_DT mass_NN spectrometer_NN for_IN further_JJ analysis_NN have_VBP not_RB
        been_VBN standardized_JJ and_CC remain_VB a_DT fertile_JJ area_NN for_IN
        investigation_NN [_NN 15_CD ]_NN ._. We_PRP choose_VBP the_DT deliberately_RB simple_JJ
        strategy_NN of_IN using_VBG Wilcoxon_NNP test_NN on_IN the_DT raw_JJ data_NN to_TO better_JJR
        understand_VB the_DT underlying_VBG properties_NNS of_IN the_DT data_NNS set_VBN ._. We_PRP
        consider_VBP this_DT simple_JJ approach_NN a_DT "_'' benchmark_NN method_NN "_'' to_TO which_WDT
        other_JJ methods_NNS can_MD be_VB compared_VBN ._. Further_RB ,_, we_PRP use_VBP Wilcoxon_NNP
        test_NN and_CC stepwise_NN discriminant_NN analysis_NN on_IN a_DT training_NN
        subset_NN consisting_VBG of_IN 80_CD cancer_NN patients_NNS and_CC 45_CD controls_NNS ,_,
        randomly_RB chosen_VBN from_IN the_DT original_JJ data_NN set_VBN ,_, to_TO develop_VB
        rules_NNS to_TO classify_VB a_DT test_NN set_VBD consisting_VBG of_IN the_DT remaining_VBG
        cancer_NN and_CC control_NN subjects_NNS ._. Disease_NN classifiers_NNS of_IN great_JJ
        sensitivity_NN and_CC specificity_NN could_MD be_VB readily_RB constructed_VBN by_IN
        visual_JJ inspection_NN and_CC manual_JJ binning_VBG of_IN M_NNP /_NN Z_NNP values_NNS based_VBN on_IN
        the_DT p-values_JJ of_IN the_DT Wilcoxon_NNP test_NN combined_VBN with_IN classical_JJ
        stepwise_NN discriminant_NN analysis_NN ._. The_DT ability_NN of_IN these_DT rules_NNS
        to_TO classify_VB disease_NN and_CC normal_JJ samples_NNS were_VBD comparable_JJ to_TO
        the_DT model_NN rule_NN published_VBN on_IN this_DT dataset_NN at_IN the_DT Clinical_NNP
        Proteomics_NNP Program_NNP Databank_NNP website_NN which_WDT was_VBD developed_VBN
        using_VBG a_DT proprietary_JJ genetic_JJ algorithm_NN ._. Further_RB ,_, in_IN
        examining_VBG all_DT M_NNP /_NN Z_NNP values_NNS ,_, the_DT M_NNP /_NN Z_NNP values_NNS that_IN discriminated_JJ
        best_JJS between_IN ovarian_NN cancer_NN and_CC control_NN were_VBD all_DT found_VBD to_TO
        be_VB less_JJR than_IN 500_CD ,_, an_DT area_NN of_IN the_DT spectrum_NN often_RB discarded_VBD
        as_IN noise_NN [_NN 10_CD ]_NN ._. These_DT findings_NNS are_VBP useful_JJ for_IN several_JJ
        reasons_NNS ._. First_LS ,_, the_DT statistical_JJ methods_NNS used_VBN in_IN this_DT study_NN
        are_VBP readily_RB available_JJ ,_, widely_RB understood_VBN ,_, and_CC can_MD be_VB
        cheaply_RB implemented_VBN ._. Secondly_RB ,_, a_DT vast_JJ amount_NN of_IN
        mathematical_JJ research_NN and_CC practical_JJ experience_NN underlies_NNS
        their_PRP$ interpretation_NN ._. Finally_RB ,_, they_PRP can_MD be_VB used_VBN to_TO discover_VB
        unexpected_JJ patterns_NNS present_JJ in_IN the_DT data_NNS set_VBN ._. These_DT patterns_NNS
        may_MD be_VB missed_VBN by_IN machine_NN learning_VBG methods_NNS that_WDT are_VBP narrowly_RB
        focused_VBN on_IN diagnostic_JJ classification_NN ,_, and_CC do_VBP not_RB present_VB
        the_DT researcher_NN with_IN a_DT broad_JJ overview_NN of_IN the_DT data_NNS ._. As_IN a_DT
        result_NN of_IN these_DT traditional_JJ studies_NNS ,_, a_DT better_JJR understanding_NN
        of_IN the_DT weaknesses_NNS and_CC possible_JJ strengths_NNS of_IN serum_NN proteomic_JJ
        profiling_VBG becomes_VBZ apparent_JJ ._.
      
      
        Results_NNS and_CC Discussion_NNP
        Based_VBN on_IN the_DT initial_JJ training_NN set_VBD ,_, the_DT intensity_NN at_IN each_DT
        of_IN the_DT consecutive_JJ 15_CD ,_, 154_CD M_NNP /_NN Z_NNP values_NNS was_VBD first_JJ compared_VBN
        using_VBG a_DT two-sided_JJ Wilcoxon_NNP test_NN (_( see_VB methods_NNS )_) Figure_NN 1_CD shows_VBZ
        the_DT pattern_NN of_IN the_DT resulting_VBG two-sided_JJ Wilcoxon_NNP test_NN
        p-values_JJ generated_VBN on_IN a_DT training_NN set_VBD consisting_VBG of_IN 80_CD
        cancer_NN patients_NNS and_CC 45_CD controls_NNS randomly_RB chosen_VBN from_IN the_DT
        larger_JJR data_NN set_VBN ,_, with_IN the_DT M_NNP /_NN Z_NNP values_NNS on_IN the_DT x-axis_JJ and_CC the_DT
        negative_JJ logarithm_NN (_( base_NN 10_CD )_) of_IN the_DT Wilcoxon_NNP test_NN p-values_JJ
        on_IN the_DT y-axis_JJ ._. There_EX are_VBP a_DT total_NN of_IN 685_CD distinct_JJ M_NNP /_NN Z_NNP values_NNS
        differing_VBG between_IN the_DT cancer_NN and_CC control_NN populations_NNS with_IN a_DT
        p-value_JJ of_IN less_JJR than_IN 10_CD -_: 6_CD ._. Also_RB of_IN note_NN in_IN this_DT
        distribution_NN is_VBZ that_IN all_DT M_NNP /_NN Z_NNP values_NNS with_IN a_DT Wilcoxon_NNP p-value_JJ
        less_JJR than_IN 10_CD -_: 12_CD are_VBP found_VBN at_IN M_NNP /_NN Z_NNP values_NNS of_IN less_JJR than_IN 500_CD ._.
        The_DT significance_NN of_IN this_DT finding_VBG will_MD be_VB discussed_VBN further_RB
        below_IN ._.
        In_IN order_NN to_TO determine_VB if_IN these_DT data_NNS could_MD be_VB used_VBN to_TO
        separate_VB normal_JJ from_IN cancer_NN ,_, we_PRP used_VBD three_CD strategies_NNS to_TO
        develop_VB rules_NNS for_IN diagnostic_JJ classification_NN ._. First_LS ,_, all_DT
        data_NNS points_NNS regardless_RB of_IN M_NNP /_NN Z_NNP value_NN were_VBD sorted_VBN from_IN most_JJS
        to_TO least_JJS significant_JJ (_( according_VBG to_TO the_DT two-sided_JJ Wilcoxon_NNP
        test_NN p-values_JJ )_) and_CC the_DT 100_CD M_NNP /_NN Z_NNP values_NNS with_IN the_DT lowest_JJS
        p-values_JJ were_VBD chosen_VBN ._. These_DT 100_CD M_NNP /_NN Z_NNP values_NNS were_VBD then_RB
        separated_JJ into_IN distinct_JJ bins_NNS by_IN sorting_VBG on_IN consecutive_JJ M_NNP /_NN Z_NNP
        and_CC requiring_VBG a_DT separation_NN of_IN at_IN least_JJS 1_CD M_NNP /_NN Z_NNP value_NN to_TO start_VB
        the_DT next_JJ bin_NN (_( 12_CD bins_NNS were_VBD detected_VBN in_IN this_DT process_NN )_) ._. The_DT
        M_NNP /_NN Z_NNP value_NN with_IN the_DT smallest_JJS p-value_JJ in_IN each_DT bin_NN was_VBD
        selected_VBN ._. The_DT results_NNS are_VBP shown_VBN in_IN Table_NNP 1_CD ._. Next_JJ ,_, stepwise_NN
        discriminate_JJ analysis_NN was_VBD performed_VBN ,_, and_CC 7_CD M_NNP /_NN Z_NNP values_NNS were_VBD
        selected_VBN for_IN Rule_NN 1_CD (_( of_IN note_NN ,_, all_DT but_CC one_CD M_NNP /_NN Z_NNP value_NN was_VBD
        below_IN 500_CD )_) ._. When_WRB this_DT rule_NN was_VBD applied_VBN to_TO the_DT entire_JJ data_NN
        set_VBN ,_, test_NN and_CC training_NN inclusive_JJ ,_, all_DT 162_CD cancer_NN and_CC 91_CD
        controls_NNS were_VBD appropriately_RB classified_VBN without_IN error_NN for_IN
        100_CD %_NN sensitivity_NN and_CC specificity_NN ._. Given_VBN that_IN the_DT
        interpretation_NN of_IN low_JJ M_NNP /_NN Z_NNP values_NNS maybe_RB problematic_JJ ,_, we_PRP next_RB
        focused_VBN attention_NN on_IN a_DT set_NN of_IN rules_NNS which_WDT met_VBD the_DT following_VBG
        requirements_NNS ._. First_LS ,_, the_DT M_NNP /_NN Z_NNP value_NN had_VBD to_TO exceed_VB 2000_CD ,_, and_CC
        the_DT Wilcoxon_NNP test_NN P-_NNP value_NN had_VBD to_TO be_VB less_JJR than_IN 10_CD -_: 6_CD ._. A_DT
        total_NN of_IN 462_CD M_NNP /_NN Z_NNP values_NNS from_IN the_DT training_NN set_VBN met_VBD these_DT
        criteria_NNS ._. As_IN shown_VBN in_IN Table_NNP 2_CD ,_, a_DT total_NN of_IN 30_CD bins_NNS were_VBD
        detected_VBN by_IN sorting_VBG on_IN consecutive_JJ M_NNP /_NN Z_NNP values_NNS as_IN above_IN ,_, and_CC
        the_DT most_RBS significant_JJ p-value_JJ from_IN each_DT bin_NN was_VBD selected_VBN for_IN
        stepwise_NN discriminant_NN analysis_NN ._. Thirteen_CD M_NNP /_NN Z_NNP values_NNS were_VBD
        retained_VBN in_IN Rule_NN 2_CD ._. In_IN the_DT training_NN set_VBD ,_, one_CD subject_JJ in_IN the_DT
        cancer_NN group_NN was_VBD misclassified_VBN as_IN normal_JJ and_CC one_CD in_IN the_DT
        control_NN group_NN was_VBD misclassified_VBN as_IN cancer_NN ._. In_IN the_DT test_NN set_VBD ,_,
        two_CD subjects_NNS from_IN the_DT control_NN group_NN were_VBD misclassified_VBN as_IN
        cancer_NN ._. Therefore_RB for_IN the_DT test_NN set_VBD ,_, the_DT sensitivity_NN was_VBD
        82_CD /_NN 82_CD or_CC 100_CD %_NN and_CC the_DT specificity_NN was_VBD 43_CD /_NN 45_CD or_CC 95_CD ._. 7_CD %_NN ._. For_IN
        the_DT test_NN and_CC training_NN set_VBN combined_VBN ,_, one_CD subject_NN was_VBD
        misclassified_VBN in_IN the_DT cancer_NN group_NN as_IN normal_JJ and_CC three_CD
        subjects_NNS were_VBD misclassified_VBN in_IN the_DT control_NN group_NN as_IN cancer_NN ._.
        Thus_RB for_IN this_DT rule_NN the_DT overall_JJ sensitivity_NN was_VBD 161_CD /_NN 162_CD or_CC
        99_CD ._. 4_LS %_NN and_CC its_PRP$ overall_JJ specificity_NN was_VBD 88_CD /_NN 91_CD or_CC 96_CD ._. 7_CD %_NN ._.
        Finally_RB ,_, Rule_NN 3_CD was_VBD constructed_VBN using_VBG the_DT 30_CD M_NNP /_NN Z_NNP values_NNS in_IN
        Rule_NN 2_CD combined_VBN with_IN four_CD M_NNP /_NN Z_NNP values_NNS 409_CD ._. 75936_CD ,_, 418_CD ._. 11364_CD ,_,
        435_CD ._. 0751_CD ,_, and_CC 464_CD ._. 3617_CD (_( all_DT also_RB used_VBN in_IN Rule_NN 1_LS )_) ._. This_DT was_VBD
        done_VBN because_IN prior_JJ studies_VBZ have_VBP indicated_VBN the_DT possible_JJ
        presence_NN of_IN low_JJ molecular_JJ weight_NN biomarkers_NNS in_IN ovarian_NN
        cancer_NN (_( see_VB below_IN )_) ._. When_WRB this_DT set_JJ of_IN M_NNP /_NN Z_NNP values_NNS was_VBD
        subjected_VBN to_TO stepwise_NN discriminant_NN analysis_NN ,_, seven_CD
        variables_NNS at_IN M_NNP /_NN Z_NNP values_NNS of_IN 418_CD ._. 1136_CD ,_, 435_CD ._. 0751_CD ,_, 464_CD ._. 3617_CD ,_,
        4003_CD ._. 645_CD ,_, 4906_CD ._. 962_CD ,_, 6599_CD ._. 8232_CD ,_, and_CC 6801_CD ._. 495_CD were_VBD retained_VBN ._.
        When_WRB Rule_NN 3_CD was_VBD applied_VBN to_TO the_DT entire_JJ data_NN set_VBN ,_, test_NN and_CC
        training_NN inclusive_JJ ,_, all_DT 162_CD cancer_NN and_CC 91_CD controls_NNS were_VBD
        appropriately_RB categorized_VBN without_IN error_NN for_IN 100_CD %_NN
        sensitivity_NN and_CC specificity_NN ._. The_DT actual_JJ classification_NN
        schema_NN for_IN all_DT three_CD rules_NNS is_VBZ shown_VBN in_IN Table_NNP 3_CD ._. The_DT results_NNS
        presented_VBN with_IN these_DT three_CD rules_NNS were_VBD all_DT achieved_VBN in_IN the_DT
        first_JJ attempt_NN ._. No_DT effort_NN was_VBD made_VBN to_TO further_VB optimize_NN these_DT
        rules_NNS ._. We_PRP next_JJ interchanged_JJ the_DT test_NN and_CC training_NN sets_NNS and_CC
        used_VBD the_DT same_JJ three_CD rule_NN development_NN strategies_NNS ._. This_DT
        resulted_VBD in_IN :_:
        1_LS )_) Rule_NN 1_CD with_IN M_NNP /_NN Z_NNP values_NNS of_IN 2_CD ._. 8234234_CD ,_, 222_CD ._. 41828_CD ,_,
        410_CD ._. 13727_CD ,_, 417_CD ._. 73207_CD ,_, 435_CD ._. 07512_CD ,_, 4027_CD ._. 2999_CD ,_, and_CC 8035_CD ._. 0581_CD ,_,
        achieved_VBD 100_CD %_NN sensitivity_NN and_CC specificity_NN on_IN both_DT the_DT test_NN
        and_CC training_NN sets_NNS ._.
        2_LS )_) Rule_NN 2_CD with_IN M_NNP /_NN Z_NNP values_NNS of_IN 3676_CD ._. 3951_CD ,_, 3937_CD ._. 7816_CD ,_,
        4003_CD ._. 6449_CD ,_, 4440_CD ._. 095_CD ,_, 5269_CD ._. 0367_CD ,_, 10511_CD ._. 699_CD ,_, 14182_CD ._. 82_CD ,_, and_CC
        17019_CD ._. 433_CD ._. This_DT rule_NN achieved_VBD 100_CD %_NN sensitivity_NN and_CC
        specificity_NN on_IN the_DT training_NN set_VBN ._. However_RB sensitivity_NN and_CC
        specificity_NN fell_VBD on_IN the_DT test_NN set_VBN to_TO 96_CD ._. 25_CD %_NN and_CC 91_CD ._. 11_CD %_NN
        respectively_RB ._.
        3_LS )_) Rule_NN 3_CD with_IN M_NNP /_NN Z_NNP values_NNS of_IN 417_CD ._. 73207_CD ,_, 435_CD ._. 07512_CD ,_,
        2666_CD ._. 361_CD ,_, 2674_CD ._. 0769_CD ,_, 3937_CD ._. 7816_CD ,_, 3991_CD ._. 8435_CD ,_, 4821_CD ._. 0481_CD ,_,
        4839_CD ._. 2088_CD ,_, 5269_CD ._. 0367_CD ,_, 7627_CD ._. 1183_CD ,_, 14182_CD ._. 82_CD ,_, and_CC 17019_CD ._. 433_CD ._.
        This_DT rule_NN achieved_VBD 100_CD %_NN sensitivity_NN and_CC specificity_NN on_IN the_DT
        training_NN set_VBN ._. On_IN the_DT test_NN set_VBD it_PRP achieved_VBD a_DT sensitivity_NN of_IN
        100_CD %_NN and_CC a_DT specificity_NN of_IN 97_CD ._. 8_CD %_NN ._. We_PRP have_VBP used_VBN a_DT strategy_NN
        identical_JJ to_TO that_DT used_VBD in_IN Rule_NN 1_CD to_TO further_VB analyze_VB this_DT
        data_NNS ._. First_LS ,_, a_DT randomly_RB ordered_VBN list_NN of_IN cancer_NN spectra_NN and_CC
        a_DT randomly_RB ordered_VBN list_NN of_IN control_NN spectra_NN were_VBD prepared_VBN ._.
        Next_JJ ,_, we_PRP assigned_VBN the_DT first_JJ 20_CD %_NN of_IN each_DT list_NN to_TO a_DT test_NN set_VBN
        and_CC the_DT remaining_VBG 80_CD %_NN to_TO a_DT training_NN set_VBN ._. The_DT process_NN was_VBD
        repeated_VBN five_CD times_NNS assigning_VBG the_DT next_JJ consecutive_JJ 20_CD %_NN of_IN
        each_DT list_NN for_IN the_DT test_NN set_VBN on_IN each_DT occasion_NN ._. The_DT results_NNS
        were_VBD very_RB similar_JJ to_TO those_DT above_IN with_IN all_DT five_CD rules_NNS
        achieving_VBG 100_CD %_NN sensitivity_NN and_CC specificity_NN ._. This_DT data_NNS is_VBZ
        posted_VBN as_IN additional_JJ data_NNS file_VBP Supplement_NNP 1_CD ._. xls_NNS ._.
        Additional_JJ File_NNP 1_CD
        This_DT Excel_NNP file_NN contains_VBZ 5_CD work_NN sheets_NNS ._. Each_DT sheet_NN
        contains_VBZ the_DT most_RBS significant_JJ 100_CD MZ_NNP values_NNS from_IN a_DT training_NN
        set_VBD consisting_VBG of_IN a_DT different_JJ 80_CD %_NN subset_NN of_IN the_DT data_NNS ._. The_DT
        MZ_NNP values_NNS have_VBP been_VBN sorted_VBN into_IN bins_NNS and_CC the_DT most_RBS
        significant_JJ MZ_NNP value_NN from_IN each_DT bin_NN (_( marked_VBD with_IN a_DT "_'' I_PRP "_'' in_IN
        column_NN E_NNP )_) was_VBD used_VBN in_IN stepwise_NN dicriminant_NN analysis_NN ._. MZ_NNP
        values_NNS retained_VBD in_IN the_DT final_JJ rule_NN are_VBP indicated_VBN with_IN an_DT "_'' s_VBZ "_''
        in_IN column_NN F_NN ._.
        Click_NNP here_RB for_IN file_NN
        The_DT presence_NN of_IN statistically_RB significant_JJ signals_NNS at_IN M_NNP /_NN Z_NNP
        values_NNS less_JJR than_IN 500_CD was_VBD unexpected_JJ as_IN some_DT investigators_NNS ,_,
        in_IN their_PRP$ systems_NNS ,_, conservatively_RB disregard_NN data_NNS beneath_IN M_NNP /_NN Z_NNP
        values_NNS of_IN 2000_CD as_IN possible_JJ noise_NN [_NN 12_CD ]_NN ._. To_TO further_VB
        investigate_VB this_DT ,_, we_PRP first_RB repeated_VBD the_DT calculation_NN of_IN
        2_CD -_: sided_VBN Wilcoxon_NNP test_NN p-values_JJ at_IN each_DT of_IN the_DT 15_CD ,_, 154_CD M_NNP /_NN Z_NNP
        values_NNS using_VBG the_DT entire_JJ data_NN set_VBN (_( see_VB Figure_NN 2_LS )_) ._. The_DT trends_NNS
        noted_VBD in_IN the_DT training_NN set_VBN were_VBD present_JJ in_IN the_DT entire_JJ data_NN
        set_VBN ,_, although_IN with_IN increased_VBN statistical_JJ significance_NN ._. For_IN
        example_NN 3_CD ,_, 591_CD of_IN the_DT 15_CD ,_, 154_CD M_NNP /_NN Z_NNP values_NNS had_VBD mean_VB intensities_NNS
        that_WDT varied_VBD between_IN cancer_NN and_CC control_NN with_IN a_DT p-value_JJ of_IN 10_CD
        -_: 6_CD or_CC less_JJR ._. In_IN a_DT sample_NN of_IN a_DT panel_NN consisting_VBG of_IN 15_CD ,_, 154_CD
        independent_JJ random_JJ sets_NNS of_IN measurements_NNS split_NN between_IN
        cancer_NN and_CC control_NN ,_, using_VBG Wilcoxon_NNP test_NN 15_CD ,_, 154_CD times_NNS with_IN
        an_DT individual_JJ significance_NN level_NN of_IN 10_CD -_: 6_CD ,_, the_DT number_NN of_IN
        false_JJ positives_NNS is_VBZ expected_VBN to_TO be_VB 0_CD ._. 015_CD ._. It_PRP is_VBZ very_RB small_JJ ._.
        Alternatively_RB ,_, in_IN the_DT above_JJ setting_VBG the_DT chance_NN that_IN at_IN
        least_JJS one_CD of_IN the_DT 15_CD ,_, 154_CD measurements_NNS would_MD have_VB a_DT p-value_JJ
        less_JJR than_IN 10_CD -_: 6_CD is_VBZ approximately_RB 1_CD ._. 5_CD %_NN ._. Thus_RB it_PRP is_VBZ extremely_RB
        unlikely_JJ that_IN a_DT false_JJ positive_NN would_MD occur_VB by_IN chance_NN alone_RB
        in_IN a_DT 15_CD ,_, 154_CD member_NN test_NN set_VBN ._. The_DT finding_NN of_IN significant_JJ
        signals_NNS at_IN M_NNP /_NN Z_NNP values_NNS less_JJR than_IN 500_CD is_VBZ consistent_JJ with_IN two_CD
        of_IN the_DT seven_CD M_NNP /_NN Z_NNP values_NNS used_VBN in_IN the_DT model_NN rule_NN published_VBN at_IN
        the_DT Clinical_NNP Proteomics_NNP Program_NNP Databank_NNP website_NN that_WDT was_VBD
        developed_VBN on_IN the_DT same_JJ data_NN set_VBN (_( see_VB Table_NNP 4_LS )_) ,_, specifically_RB
        M_NNP /_NN Z_NNP values_NNS 435_CD ._. 46452_CD (_( p-value_JJ =_SYM 9_CD ._. 08_CD ×_NN 10_CD -_: 372_CD ndmost_NN
        significant_JJ of_IN 9_CD values_NNS in_IN its_PRP$ bin_NN )_) and_CC 465_CD ._. 56916_CD (_( p-value_JJ
        =_SYM 2_CD ._. 50_CD ×_NN 10_CD -_: 286_CD thmost_NN significant_JJ of_IN the_DT 7_CD M_NNP /_NN Z_NNP values_NNS
        found_VBD in_IN its_PRP$ bin_NN )_) [_NN 7_CD ]_NN ._. These_DT values_NNS correspond_VB to_TO M_NNP /_NN Z_NNP
        values_NNS of_IN 435_CD ._. 0751_CD and_CC 464_CD ._. 3617_CD used_VBN in_IN Rule_NN 1_CD ._. As_IN shown_VBN in_IN
        Figure_NN 3_CD ,_, each_DT of_IN these_DT two_CD pairs_NNS of_IN M_NNP /_NN Z_NNP values_NNS are_VBP
        surprisingly_RB effective_JJ at_IN separating_VBG the_DT 162_CD cancer_NN
        subjects_NNS from_IN the_DT 91_CD control_NN subjects_NNS with_IN an_DT advantage_NN
        noted_VBD with_IN the_DT first_JJ pair_NN (_( compare_VB panel_NN A_DT with_IN B_NNP )_) ._. Even_RB
        more_RBR interesting_JJ is_VBZ the_DT finding_VBG that_IN significant_JJ M_NNP /_NN Z_NNP values_NNS
        found_VBD in_IN the_DT first_JJ Rule_NN 1_CD included_VBD the_DT M_NNP /_NN Z_NNP values_NNS of_IN
        2_CD ._. 7921478_CD and_CC 245_CD ._. 53704_CD ._. As_IN shown_VBN in_IN Figure_NN 3_CD ,_, panel_NN C_NNP ,_,
        these_DT two_CD values_NNS can_MD also_RB significantly_RB separate_VB the_DT 162_CD
        cancer_NN subjects_NNS from_IN the_DT 91_CD control_NN subjects_NNS ._. The_DT
        interpretation_NN of_IN these_DT values_NNS is_VBZ problematic_JJ ,_, given_VBN the_DT
        low_JJ M_NNP /_NN Z_NNP values_NNS involved_VBN ._. In_IN order_NN to_TO evaluate_VB these_DT
        findings_NNS ,_, we_PRP first_RB investigated_VBN whether_IN data_NNS normalization_NN
        as_IN described_VBN at_IN the_DT Clinical_NNP Proteomics_NNP Data_NNP Bank_NNP [_NN 5_CD ]_NN
        could_MD influence_VB the_DT Wilcoxon_NNP test_NN p-values_JJ found_VBD using_VBG the_DT
        raw_JJ data_NN (_( see_VB methods_NNS )_) ._. Several_JJ points_NNS were_VBD chosen_VBN ,_, and_CC no_DT
        effect_NN was_VBD noted_VBN on_IN the_DT p-values_JJ (_( see_VB Table_NNP 5_LS )_) ._. We_PRP further_RBR
        analyzed_VBD several_JJ selected_VBN low_JJ M_NNP /_NN Z_NNP values_NNS ,_, less_JJR than_IN 500_CD ._. In_IN
        this_DT process_NN ,_, the_DT cancer_NN and_CC control_NN data_NNS were_VBD pooled_VBN ._. The_DT
        pooled_VBN data_NN were_VBD randomly_RB partitioned_JJ between_IN a_DT set_VBN
        containing_VBG 91_CD members_NNS and_CC a_DT set_VBN containing_VBG 162_CD members_NNS ._. The_DT
        Wilcoxon_NNP test_NN was_VBD then_RB run_VB on_IN the_DT randomized_JJ set_VBN ._. The_DT
        process_NN was_VBD repeated_VBN 10_CD ,_, 000_CD times_NNS ,_, and_CC the_DT lowest_JJS p-values_JJ
        were_VBD chosen_VBN ._. As_IN shown_VBN in_IN Table_NNP 5_CD ,_, the_DT lowest_JJS p-values_JJ
        generated_VBN by_IN the_DT permutation_NN process_NN were_VBD on_IN the_DT order_NN of_IN
        0_CD ._. 0001_CD ,_, as_IN expected_VBN given_VBN the_DT number_NN of_IN permutations_NNS
        tested_VBN ._. Thus_RB ,_, it_PRP is_VBZ highly_RB unlikely_JJ that_IN either_DT data_NNS
        normalization_NN or_CC a_DT chance_NN distribution_NN could_MD have_VB accounted_VBN
        for_IN the_DT highly_RB significant_JJ p-values_JJ noted_VBD in_IN the_DT M_NNP /_NN Z_NNP region_NN
        less_JJR than_IN 500_CD ._. Finally_RB ,_, it_PRP is_VBZ interesting_JJ to_TO note_VB that_IN the_DT
        remaining_VBG five_CD values_NNS in_IN the_DT Clinical_NNP Proteomics_NNP Program_NNP
        Databank_NNP model_NN rule_NN all_DT have_VBP M_NNP /_NN Z_NNP values_NNS greater_JJR than_IN 2000_CD
        and_CC relatively_RB high_JJ p-values_JJ ._. Specifically_RB the_DT remaining_VBG
        values_NNS are_VBP (_( note_NN that_IN the_DT p-values_JJ are_VBP calculated_VBN from_IN the_DT
        entire_JJ data_NN set_VBN )_) :_:
        1_LS )_) M_NNP /_NN Z_NNP =_SYM 2760_CD ._. 6685_CD ,_, p_NN =_SYM 0_CD ._. 24_CD
        2_LS )_) M_NNP /_NN Z_NNP =_SYM 19643_CD ._. 409_CD ,_, p_NN =_SYM 0_CD ._. 52_CD
        3_LS )_) M_NNP /_NN Z_NNP =_SYM 6631_CD ._. 7043_CD ,_, p_NN =_SYM 9_CD ._. 0_CD ×_NN 10_CD -_: 4_CD
        4_LS )_) M_NNP /_NN Z_NNP =_SYM 14051_CD ._. 976_CD ,_, p_NN =_SYM 1_CD ._. 8_CD ×_NN 10_CD -_: 8_CD
        5_LS )_) M_NNP /_NN Z_NNP =_SYM 3497_CD ._. 5508_CD ,_, p_NN =_SYM 1_CD ._. 4_CD ×_NN 10_CD -_: 6_CD
        By_IN contrast_NN all_PDT the_DT M_NNP /_NN Z_NNP values_NNS used_VBN in_IN Rule_NN 1_CD have_VBP
        p-values_JJ less_JJR than_IN 10_CD -_: 26_CD (_( compare_VB Table_NNP 1_CD with_IN Table_NNP 4_LS )_) ._.
        There_EX are_VBP several_JJ non-exclusive_JJ explanations_NNS for_IN the_DT
        presence_NN of_IN significant_JJ P-_NNP values_NNS in_IN M_NNP /_NN Z_NNP region_NN less_JJR than_IN
        500_CD ._. First_LS ,_, these_DT may_MD actually_RB represent_VB biomarkers_NNS that_WDT
        correlate_VBP with_IN ovarian_NN cancer_NN ._. The_DT disease_NN process_NN may_MD
        influence_VB the_DT serum_NN concentration_NN of_IN lipids_NNS ,_, or_CC other_JJ small_JJ
        molecules_NNS that_IN either_DT bind_NN to_TO the_DT chip_NN directly_RB or_CC through_IN
        a_DT complex_JJ formation_NN with_IN other_JJ macromolecules_NNS (_( e_SYM ._. g_SYM ._. ,_,
        binding_VBG to_TO a_DT receptor_NN )_) ._. For_IN example_NN ,_, the_DT lysophospholipids_NNS
        represent_VBP a_DT class_NN of_IN compounds_NNS that_WDT have_VBP an_DT important_JJ role_NN
        in_IN extracellular_NN signaling_VBG ._. Lysophophatidic_NNP Acid_NNP (_( LPA_NNP )_) is_VBZ a_DT
        member_NN of_IN this_DT class_NN of_IN compounds_NNS ,_, and_CC its_PRP$ plasma_NN levels_NNS
        have_VBP been_VBN proposed_VBN as_IN a_DT potential_JJ biomarker_NN for_IN ovarian_NN
        cancer_NN [_NN 16_CD 17_CD ]_NN ._. LPA_NNP is_VBZ a_DT family_NN of_IN related_VBN molecules_NNS
        with_IN molecular_JJ weights_NNS in_IN the_DT vicinity_NN of_IN 400_CD to_TO 600_CD
        Daltons_NNP ,_, and_CC a_DT variety_NN of_IN LPA_NNP species_NNS has_VBZ been_VBN reported_VBN to_TO
        be_VB increased_VBN in_IN malignant_JJ ascites_NNS from_IN patients_NNS with_IN
        ovarian_NN cancer_NN as_IN detected_VBN by_IN electrospray_NN ionization_NN mass_NN
        spectrometry_NN (_( ESI-MS_NNP )_) [_NN 18_CD ]_NN ._. LPA_NNP related_VBD species_NNS have_VBP
        also_RB been_VBN reported_VBN to_TO be_VB increased_VBN in_IN plasma_NN samples_NNS from_IN
        patients_NNS with_IN ovarian_NN cancer_NN using_VBG a_DT combination_NN of_IN thin_JJ
        layer_NN chromatography_NN (_( to_TO isolate_VB an_DT "_'' LPA_NNP band_NN "_'' from_IN patient_NN
        plasma_NN )_) followed_VBN by_IN ESI-MS_NNP ._. This_DT study_NN reported_VBD significant_JJ
        LPA_NNP increases_NNS in_IN cancer_NN samples_NNS with_IN increased_VBN intensities_NNS
        noted_VBD at_IN M_NNP /_NN Z_NNP values_NNS of_IN 409_CD ,_, 433_CD -_: 437_CD ,_, 457_CD ,_, 481_CD -_: 482_CD ,_, 571_CD ,_,
        599_CD ,_, and_CC 619_CD ._. This_DT report_NN also_RB reviews_VBZ the_DT evidence_NN that_IN
        these_DT M_NNP /_NN Z_NNP values_NNS are_VBP consistent_JJ with_IN LPA_NNP family_NN members_NNS [_NN
        19_CD ]_NN ._. Figure_NN 4_CD shows_VBZ the_DT average_JJ intensities_NNS and_CC p-values_JJ
        for_IN both_DT the_DT cancer_NN and_CC control_NN groups_NNS in_IN the_DT region_NN
        between_IN M_NNP /_NN Z_NNP values_NNS of_IN 410_CD to_TO 470_CD ._. Among_IN other_JJ features_NNS ,_, an_DT
        increase_NN in_IN the_DT mean_JJ intensity_NN for_IN cancers_NNS at_IN a_DT peak_NN
        centered_VBN at_IN an_DT M_NNP /_NN Z_NNP of_IN 459_CD is_VBZ noted_VBN ._. However_RB ,_, also_RB of_IN note_NN
        in_IN this_DT region_NN are_VBP :_:
        1_LS )_) M_NNP /_NN Z_NNP =_SYM 464_CD ._. 3617_CD with_IN a_DT p-value_JJ less_JJR than_IN 6_CD ._. 8_CD ×_NN 10_CD -_: 35_CD ,_,
        that_IN correlates_NNS with_IN a_DT shoulder_NN in_IN a_DT secondary_JJ peak_NN at_IN
        about_IN 463_CD ,_, that_WDT is_VBZ decreased_VBN in_IN cancer_NN patients_NNS (_( average_JJ
        intensity_NN 17_CD ._. 5_LS for_IN cancer_NN versus_CC 23_CD ._. 6_CD for_IN controls_NNS )_) ._.
        2_LS )_) M_NNP /_NN Z_NNP =_SYM 435_CD ._. 0751_CD with_IN a_DT p-value_JJ of_IN less_JJR than_IN 3_CD ._. 9_CD ×_NN 10_CD
        -_: 37_CD ,_, that_IN corresponds_NNS to_TO a_DT peak_NN with_IN increased_VBN intensity_NN in_IN
        cancer_NN (_( average_JJ intensity_NN 33_CD for_IN cancer_NN versus_CC 25_CD ._. 5_LS for_IN
        controls_NNS )_) ._.
        3_LS )_) M_NNP /_NN Z_NNP =_SYM 417_CD ._. 73207_CD with_IN a_DT p-value_JJ less_JJR than_IN 6_CD ._. 2_CD ×_NN 10_CD
        -_: 35_CD ,_, that_IN corresponds_NNS to_TO a_DT peak_NN that_WDT is_VBZ decreased_VBN in_IN cancer_NN
        (_( average_JJ intensity_NN 39_CD ._. 5_LS for_IN cancer_NN versus_CC 47_CD ._. 4_LS for_IN
        controls_NNS )_)
        The_DT identity_NN of_IN the_DT molecules_NNS responsible_JJ for_IN these_DT
        differences_NNS cannot_NN be_VB determined_VBN from_IN this_DT data_NNS ._. However_RB ,_,
        it_PRP is_VBZ possible_JJ that_IN in_IN some_DT cases_NNS they_PRP may_MD relate_VB to_TO the_DT
        LPA_NNP family_NN of_IN molecules_NNS ,_, or_CC to_TO alterations_NNS in_IN proteins_NNS that_WDT
        bind_NN LPA_NNP family_NN members_NNS ._.
        Other_JJ explanations_NNS for_IN the_DT presence_NN of_IN statistically_RB
        significant_JJ bands_NNS of_IN low_JJ M_NNP /_NN Z_NNP include_VBP degradation_NN products_NNS
        of_IN higher_JJR molecular_JJ weight_NN macromolecules_NNS or_CC a_DT matrix_NN
        effect_NN ._. For_IN example_NN ,_, if_IN a_DT set_NN of_IN proteins_NNS exist_VBP that_WDT are_VBP
        expressed_VBN at_IN different_JJ levels_NNS between_IN cancer_NN and_CC control_NN
        subjects_NNS but_CC have_VBP a_DT common_JJ domain_NN ,_, then_RB a_DT common_JJ product_NN
        ion_NN of_IN lower_JJR M_NNP /_NN Z_NNP may_MD be_VB generated_VBN that_WDT would_MD represent_VB a_DT
        summation_NN of_IN all_PDT the_DT changes_NNS in_IN expression_NN of_IN the_DT group_NN of_IN
        proteins_NNS ,_, and_CC might_MD thus_RB have_VB greater_JJR statistical_JJ
        significance_NN than_IN the_DT changes_NNS associated_VBN with_IN any_DT single_JJ
        high_JJ M_NNP /_NN Z_NNP value_NN ._. Similarly_RB ,_, a_DT set_NN of_IN low_JJ M_NNP /_NN Z_NNP molecules_NNS
        (_( e_SYM ._. g_SYM ._. ,_, energy-absorbing_JJ molecule_NN or_CC matrix_NN )_) that_IN interacts_NNS
        differently_RB in_IN a_DT protein_NN environment_NN that_WDT differs_VBZ markedly_RB
        between_IN cancer_NN and_CC control_NN could_MD hypothetically_RB generate_VB a_DT
        similar_JJ phenomenon_NN ._. However_RB ,_, it_PRP is_VBZ difficult_JJ to_TO apply_VB any_DT
        of_IN the_DT above_JJ explanations_NNS to_TO the_DT very_RB low_JJ M_NNP /_NN Z_NNP values_NNS such_JJ
        as_IN 2_CD ._. 7921478_CD and_CC 245_CD ._. 53704_CD ,_, although_IN in_IN the_DT last_JJ case_NN an_DT
        extremely_RB small_JJ organic_JJ molecule_NN is_VBZ possible_JJ ._.
        Alternatively_RB ,_, there_EX maybe_RB some_DT unexpected_JJ experimental_JJ
        bias_NN or_CC systematic_JJ error_NN that_IN accounts_NNS for_IN low_JJ M_NNP /_NN Z_NNP
        discrimination_NN ._. This_DT could_MD occur_VB at_IN any_DT experimental_JJ step_NN ,_,
        and_CC might_MD include_VB medication_NN or_CC lifestyle_NN change_NN that_WDT
        occurs_VBZ in_IN patients_NNS who_WP learn_VBP they_PRP have_VBP a_DT cancer_NN diagnosis_NN ,_,
        variation_NN in_IN sample_NN collection_NN ,_, processing_NN and_CC
        preservation_NN ,_, as_RB well_RB as_IN bias_NN introduced_VBN at_IN the_DT time_NN of_IN
        analysis_NN ._. In_IN the_DT case_NN of_IN LPA_NNP ,_, increased_VBN plasma_NN levels_NNS may_MD
        be_VB associated_VBN with_IN platelet_NN activation_NN ._. Another_DT group_NN
        trying_VBG to_TO repeat_VB the_DT observations_NNS of_IN increased_VBN levels_NNS of_IN
        LPA_NNP associated_VBN with_IN ovarian_NN cancer_NN concluded_VBD that_IN there_EX was_VBD
        no_DT diagnostic_JJ value_NN in_IN the_DT assay_NN ,_, and_CC attributed_VBD the_DT
        discrepant_NN findings_NNS as_RB possibly_RB related_VBN to_TO different_JJ sample_NN
        centrifugation_NN protocols_NNS used_VBN by_IN the_DT two_CD groups_NNS to_TO remove_VB
        platelets_NNS from_IN the_DT samples_NNS prior_RB to_TO analysis_NN [_NN 20_CD ]_NN ._.
        However_RB ,_, LPA_NNP continues_VBZ to_TO be_VB actively_RB evaluated_VBN for_IN its_PRP$
        clinical_JJ utility_NN [_NN 21_CD ]_NN ._.
      
      
        Conclusions_NNP
        Serum_NNP proteomic_JJ profiling_VBG is_VBZ a_DT new_JJ approach_NN to_TO cancer_NN
        diagnosis_NN ._. However_RB it_PRP confronts_VBZ a_DT challenging_VBG environment_NN ,_,
        as_IN it_PRP combines_VBZ measurement_NN technologies_NNS that_WDT are_VBP new_JJ in_IN the_DT
        clinical_JJ setting_NN with_IN novel_NN approaches_NNS to_TO processing_NN and_CC
        interpreting_VBG high_JJ dimensional_NN data_NNS ._. Further_RB ,_, controlling_VBG
        large_JJ clinical_JJ studies_NNS can_MD be_VB challenging_VBG even_RB in_IN more_RBR
        established_JJ settings_NNS ._. Nevertheless_RB ,_, it_PRP represents_VBZ an_DT
        advance_NN in_IN the_DT ability_NN to_TO diagnose_NN and_CC understand_VB illness_NN ._.
        The_DT results_NNS presented_VBN in_IN this_DT study_NN are_VBP useful_JJ for_IN several_JJ
        reasons_NNS ._. First_LS ,_, in_IN regard_NN to_TO disease_NN classification_NN ,_,
        advanced_VBD data_NNS mining_NN techniques_NNS should_MD be_VB benchmarked_JJ
        against_IN traditional_JJ methods_NNS when_WRB possible_JJ ._. Further_RB
        identical_JJ training_NN sets_NNS should_MD be_VB defined_VBN for_IN such_JJ a_DT
        comparison_NN as_IN results_NNS may_MD very_RB depending_VBG on_IN the_DT samples_NNS
        chosen_VBN for_IN inclusion_NN in_IN the_DT training_NN set_VBN ._. The_DT development_NN
        of_IN disease_NN classifiers_NNS using_VBG routine_JJ analysis_NN proved_VBD to_TO be_VB
        straightforward_JJ ,_, and_CC resulted_VBD in_IN excellent_JJ performance_NN in_IN
        both_DT the_DT test_NN and_CC training_NN sets_NNS (_( e_SYM ._. g_SYM ._. 100_CD %_NN sensitivity_NN and_CC
        specificity_NN for_IN Rules_NNPS 1_CD and_CC 3_CD in_IN the_DT first_JJ training_NN set_VBN )_) ._.
        In_IN particular_JJ these_DT preliminary_JJ data_NN suggest_VBP that_IN these_DT two_CD
        rules_NNS may_MD be_VB specific_JJ enough_RB to_TO scale_VB to_TO larger_JJR population_NN
        trials_NNS without_IN generating_VBG an_DT unacceptably_RB high_JJ false_JJ
        positive_JJ rate_NN ._. This_DT study_NN also_RB confirms_VBZ that_IN a_DT classifier_NN
        could_MD be_VB developed_VBN with_IN M_NNP /_NN Z_NNP values_NNS greater_JJR than_IN 2000_CD ._. This_DT
        indicates_VBZ that_DT information_NN regarding_VBG the_DT difference_NN between_IN
        cancer_NN and_CC control_NN is_VBZ present_JJ throughout_IN the_DT entire_JJ M_NNP /_NN Z_NNP
        region_NN studied_VBD ,_, a_DT result_NN entirely_RB consistent_JJ with_IN the_DT
        observed_VBN Wilcoxon_NNP test_NN p-values_JJ ._. Secondly_RB ,_, routine_JJ analysis_NN
        allows_VBZ investigators_NNS to_TO rapidly_RB review_VB the_DT data_NNS for_IN their_PRP$
        general_JJ trends_NNS ,_, and_CC correlate_VBP the_DT findings_NNS with_IN other_JJ
        information_NN ._. The_DT findings_NNS of_IN significant_JJ discrimination_NN
        between_IN cancer_NN and_CC control_NN groups_NNS at_IN low_JJ M_NNP /_NN Z_NNP values_NNS
        indicates_VBZ that_DT attention_NN should_MD be_VB focused_VBN in_IN this_DT region_NN ._.
        In_IN particular_JJ ,_, if_IN experimental_JJ bias_NN and_CC noise_NN effects_NNS can_MD
        be_VB excluded_VBN ,_, this_DT region_NN may_MD prove_VB to_TO offer_VB the_DT optimum_JJ for_IN
        ovarian_NN cancer_NN diagnostic_JJ test_NN development_NN ._. On_IN the_DT other_JJ
        hand_NN ,_, if_IN bias_NN cannot_NN be_VB excluded_VBN ,_, the_DT possibility_NN must_MD be_VB
        entertained_VBN that_IN higher_JJR M_NNP /_NN Z_NNP values_NNS may_MD also_RB have_VB been_VBN
        similarly_RB affected_VBN ._. In_IN order_NN to_TO address_VB these_DT issues_NNS ,_,
        consideration_NN may_MD be_VB given_VBN to_TO using_VBG mass_NN spectrometry_NN
        methods_NNS with_IN increased_VBN sensitivity_NN in_IN the_DT low_JJ M_NNP /_NN Z_NNP region_NN ._.
        The_DT experimental_JJ conditions_NNS used_VBN to_TO physically_RB bind_NN the_DT
        serum_NN samples_NNS to_TO the_DT chip_NN prior_RB to_TO analysis_NN may_MD also_RB prove_VB
        critical_JJ ,_, and_CC should_MD be_VB consistent_JJ with_IN those_DT used_VBN in_IN
        collecting_VBG the_DT current_JJ data_NN set_VBN ._. Also_RB ,_, the_DT possibility_NN that_IN
        the_DT changes_NNS in_IN the_DT low_JJ M_NNP /_NN Z_NNP region_NN may_MD represent_VB an_DT additive_JJ
        effect_NN caused_VBN by_IN differing_VBG protein_NN environments_NNS between_IN
        cancer_NN and_CC normal_JJ may_MD be_VB approached_VBN by_IN intentionally_RB
        spiking_VBG samples_NNS with_IN panels_NNS of_IN known_VBN proteins_NNS ,_, and_CC
        determining_VBG if_IN there_EX is_VBZ an_DT effect_NN on_IN the_DT spectra_NN in_IN the_DT low_JJ
        M_NNP /_NN Z_NNP region_NN ._. The_DT use_NN of_IN internal_JJ standards_NNS to_TO normalize_VB this_DT
        type_NN of_IN experimental_JJ system_NN in_IN general_JJ may_MD also_RB be_VB
        considered_VBN ._. As_IN with_IN all_DT clinical_JJ test_NN development_NN ,_,
        confirmation_NN of_IN results_NNS in_IN independent_JJ laboratories_NNS running_VBG
        blinded_JJ samples_NNS will_MD remain_VB the_DT gold_NN standard_JJ in_IN ruling_NN out_RP
        the_DT possible_JJ effects_NNS of_IN bias_NN ,_, unless_IN the_DT sample_NN set_VBD itself_PRP
        contains_VBZ the_DT bias_NN ._. Particular_NNP attention_NN should_MD be_VB paid_VBN to_TO
        pre-analytic_JJ causes_NNS of_IN bias_NN that_WDT may_MD influence_VB the_DT serum_NN
        proteome_NN ._. In_IN particular_JJ the_DT coagulation_NN and_CC complement_VB
        systems_NNS should_MD be_VB considered_VBN as_IN potential_JJ sources_NNS of_IN noise_NN
        in_IN this_DT context_NN ,_, as_IN both_DT are_VBP activated_VBN during_IN serum_NN sample_NN
        collection_NN and_CC generate_VB low_JJ molecular_JJ weight_NN products_NNS ._.
        These_DT products_NNS are_VBP undesirable_JJ for_IN two_CD reasons_NNS ._. First_LS ,_, if_IN a_DT
        putative_JJ tumor_NN biomarker_NN (_( e_SYM ._. g_SYM ._. LPA_NNP )_) is_VBZ a_DT member_NN of_IN a_DT
        pathway_NN altered_VBN during_IN serum_NN sample_NN collection_NN ,_, changes_NNS
        between_IN plasma_NN levels_NNS of_IN cancer_NN and_CC control_NN subjects_NNS may_MD be_VB
        obscured_VBD ._. Secondly_RB ,_, the_DT generation_NN of_IN activation_NN products_NNS
        may_MD simply_RB complicate_VB the_DT spectrum_NN ._. Also_RB ,_, sample_NN collection_NN
        practices_NNS should_MD be_VB rigorously_RB defined_VBN ,_, and_CC include_VBP
        submitting_VBG matched_VBN control_NN and_CC cancer_NN samples_NNS from_IN all_DT
        centers_NNS participating_VBG in_IN the_DT study_NN ._. Matching_NNP for_IN age_NN and_CC
        menopausal_NN status_NN should_MD be_VB considered_VBN ._. For_IN example_NN ,_, in_IN the_DT
        data_NNS set_VBN used_VBN in_IN this_DT study_NN ,_, the_DT mean_JJ age_NN of_IN the_DT control_NN
        group_NN was_VBD 47_CD years_NNS and_CC the_DT cancer_NN group_NN 60_CD years_NNS ._. It_PRP is_VBZ
        noteworthy_JJ that_IN the_DT average_JJ age_NN of_IN menopause_NN is_VBZ
        approximately_RB 51_CD years_NNS [_NN 22_CD ]_NN ._. This_DT may_MD introduce_VB a_DT bias_NN
        in_IN the_DT results_NNS reported_VBD in_IN this_DT study_NN as_RB well_RB as_IN all_DT others_NNS
        derived_VBN from_IN this_DT dataset_NN ._. Finally_RB ,_, the_DT steps_NNS associated_VBN
        with_IN sample_NN collection_NN ,_, processing_NN ,_, and_CC binding_VBG to_TO the_DT chip_NN
        may_MD represent_VB a_DT particularly_RB fertile_JJ area_NN for_IN research_NN ._. Any_DT
        combination_NN of_IN such_JJ steps_NNS may_MD significantly_RB alter_VB the_DT
        molecular_JJ subset_NN of_IN the_DT sample_NN that_WDT can_MD be_VB successfully_RB
        analyzed_VBN ._.
        However_RB ,_, the_DT ability_NN to_TO discriminate_JJ between_IN cancer_NN and_CC
        control_NN based_VBN on_IN the_DT M_NNP /_NN Z_NNP values_NNS of_IN 2_CD ._. 79_CD and_CC 245_CD ._. 5_LS reveals_VBZ
        the_DT presence_NN of_IN a_DT significant_JJ experimental_JJ bias_NN not_RB related_VBD
        to_TO disease_NN pathology_NN ,_, that_IN likely_JJ involves_VBZ machine_NN noise_NN
        and_CC matrix_NN effects_NNS ._. This_DT is_VBZ particularly_RB true_JJ of_IN the_DT M_NNP /_NN Z_NNP
        value_NN at_IN 2_CD ._. 79_CD which_WDT represents_VBZ a_DT bias_NN of_IN the_DT mass_NN
        spectrometer_NN instrument_NN itself_PRP ._. If_IN this_DT is_VBZ the_DT case_NN the_DT
        higher_JJR M_NNP /_NN Z_NNP regions_NNS may_MD also_RB be_VB affected_VBN ._. These_DT findings_NNS
        indicate_VBP that_IN any_DT rule_NN derived_VBN from_IN this_DT data_NNS set_VBN ,_,
        including_VBG the_DT ones_NNS presented_VBN in_IN this_DT paper_NN ,_, may_MD be_VB
        detecting_VBG differences_NNS in_IN experimental_JJ bias_NN and_CC not_RB disease_NN
        pathology_NN ._. Investigators_NNS in_IN this_DT field_NN may_MD minimize_VB their_PRP$
        chances_NNS of_IN false_JJ discovery_NN by_IN careful_JJ experimental_JJ design_NN
        and_CC by_IN using_VBG routine_JJ statistical_JJ methods_NNS to_TO both_DT overview_NN
        the_DT data_NNS (_( in_IN an_DT intentional_JJ search_NN for_IN bias_NN )_) as_RB well_RB as_IN a_DT
        benchmark_NN for_IN comparison_NN with_IN other_JJ data_NNS mining_NN
        algorithms_NNS ._.
      
      
        Methods_NNP
        A_DT training_NN set_VBN was_VBD formed_VBN by_IN randomly_RB sampling_VBG 45_CD
        spectra_NN out_IN of_IN the_DT 91_CD controls_NNS and_CC 80_CD spectra_NN out_IN of_IN the_DT
        162_CD cancer_NN cases_NNS (_( see_VB Figure_NN 1_LS )_) ._. Those_DT spectra_NN that_WDT were_VBD in_IN
        the_DT original_JJ data_NN set_VBN but_CC not_RB in_IN the_DT training_NN set_VBN were_VBD
        considered_VBN in_IN a_NNP '_POS test_NN '_'' set_VBN ._. Two-sided_NNP Wilcoxon_NNP test_NN was_VBD
        used_VBN to_TO compare_VB the_DT intensity_NN between_IN the_DT controls_NNS and_CC
        cancers_NNS in_IN the_DT training_NN set_VBN at_IN each_DT of_IN the_DT 15_CD ,_, 154_CD M_NNP /_NN Z_NNP
        values_NNS ._. We_PRP then_RB selected_VBD a_DT subset_NN of_IN the_DT M_NNP /_NN Z_NNP values_NNS with_IN
        the_DT lowest_JJS Wilcoxon_NNP test_NN p-values_JJ (_( see_VB the_DT Results_NNS section_NN
        for_IN details_NNS )_) ._. We_PRP sorted_VBN on_IN consecutive_JJ M_NNP /_NN Z_NNP values_NNS to_TO get_VB
        bins_NNS ._. A_DT separation_NN of_IN at_IN least_JJS one_CD M_NNP /_NN Z_NNP value_NN was_VBD required_VBN
        to_TO start_VB the_DT next_JJ bin_NN ._. The_DT lowest_JJS p-value_JJ in_IN each_DT bin_NN was_VBD
        selected_VBN and_CC the_DT corresponding_JJ M_NNP /_NN Z_NNP value_NN was_VBD used_VBN in_IN
        stepwise_NN discriminant_NN analysis_NN to_TO determine_VB the_DT subset_NN of_IN
        M_NNP /_NN Z_NNP values_NNS that_IN best_JJS discriminated_JJ cancer_NN from_IN control_NN in_IN
        the_DT training_NN set_VBN ._. The_DT criteria_NNS were_VBD applied_VBN to_TO the_DT test_NN
        data_NN set_VBN ,_, and_CC sensitivity_NN and_CC specificity_NN were_VBD computed_JJ ._.
        All_DT the_DT analyses_NNS were_VBD performed_VBN in_IN SAS_NNP Version_NNP 8_CD ._. 2_CD (_( A_DT
        statistical_JJ package_NN from_IN SAS_NNP Institute_NNP Inc_NNP ._. ,_, Cary_NNP ,_, NC_NNP ,_, USA_NNP )_)
        on_IN a_DT personal_JJ computer_NN ._. Wilcoxon_NNP test_NN was_VBD performed_VBN using_VBG
        NPAR_NNP 1_CD WAY_NNP procedure_NN in_IN SAS_NNP ,_, stepwise_NN discriminant_NN analysis_NN
        was_VBD performed_VBN using_VBG STEPDISC_NNP procedure_NN in_IN SAS_NNP ,_, and_CC
        discriminant_NN analysis_NN was_VBD performed_VBN using_VBG DISCRIM_NNP procedure_NN
        in_IN SAS_NNP [_NN 23_CD ]_NN ._.
        To_TO normalize_VB the_DT data_NNS ,_, the_DT procedure_NN outlined_VBN by_IN the_DT
        Clinical_NNP Proteomics_NNP Program_NNP Databank_NNP was_VBD used_VBN [_NN 24_CD ]_NN ._. The_DT
        cancer_NN and_CC control_NN values_NNS for_IN each_DT M_NNP /_NN Z_NNP were_VBD given_VBN
        respective_JJ labels_NNS ,_, and_CC the_DT data_NNS were_VBD then_RB pooled_VBN and_CC
        normalized_JJ using_VBG the_DT formula_NN NV_NNP =_SYM (_( V-M_NNP in_IN )_) /_NN (_( Max_NNP -_: Min_NNP )_) ._. In_IN
        this_DT expression_NN ,_, Min_NNP is_VBZ the_DT minimum_JJ intensity_NN of_IN the_DT pooled_VBN
        samples_NNS ,_, Max_NNP represents_VBZ the_DT maximum_NN intensity_NN found_VBD in_IN the_DT
        pooled_VBN samples_NNS ,_, and_CC NV_NNP represents_VBZ the_DT normalized_JJ value_NN ._.
        Using_VBG this_DT procedure_NN ,_, the_DT data_NNS intensities_NNS will_MD all_DT fall_VB
        between_IN 0_CD and_CC 1_CD ._. The_DT data_NNS points_NNS were_VBD sorted_VBN into_IN cancer_NN
        and_CC controls_NNS ,_, and_CC the_DT p-values_JJ were_VBD calculated_VBN ._.
      
      
        Authors_NNP '_'' contributions_NNS
        JMS_NNP conceived_VBD of_IN the_DT studies_NNS and_CC developed_VBD the_DT initial_JJ
        process_NN for_IN selecting_VBG diagnostic_JJ rules_NNS ._. MZ_NNP performed_VBD the_DT
        statistical_JJ analysis_NN and_CC further_RBR refined_VBN the_DT rules_NNS with_IN
        stepwise_NN discrminant_NN analysis_NN ._. All_DT authors_NNS read_VBP and_CC agreed_VBD
        with_IN the_DT final_JJ manuscript_NN ._.
      
    
  
